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Summary
Retinoic acid (RA) induces proliferation arrest, differ-
entiation, and apoptosis, and defects in retinoic acid
receptor (RAR) signaling have been implicated in can-
cer. The human tumor antigen PRAME is overex-
pressed in a variety of cancers, but its function has re-
mained unclear. We identify here PRAME as a dominant
repressor of RAR signaling. PRAME binds to RAR in
the presence of RA, preventing ligand-induced receptor
activation and target gene transcription through recruit-
ment of Polycomb proteins. PRAME is present at RAR
target promoters and inhibits RA-induced differentia-
tion, growth arrest, and apoptosis. Conversely, knock-
down of PRAME expression by RNA interference in RA-
resistant human melanoma restores RAR signaling
and reinstates sensitivity to the antiproliferative ef-
fects of RA in vitro and in vivo. Our data suggest that
overexpression of PRAME frequently observed in hu-
man cancers confers growth or survival advantages
by antagonizing RAR signaling.
Introduction
The family of nuclear receptors (NR) consists of ligand-
regulated transcription factors that control a wide
range of physiological processes in development, dif-
ferentiation, and homeostasis. Nuclear receptors are
composed of a series of conserved domains (named
A-F). Their modular structure reveals distinct functional
domains, including an N-terminal activation function 1
(AF-1), the DNA binding domain, the hinge region, and
a C-terminal ligand binding domain (LBD), which con-
tains a ligand-dependent AF-2 domain (Freedman,
1999). Nuclear receptor function requires receptor di-
merization, and based on the mode of dimerization, two
subtypes of nuclear receptors can be distinguished.
The steroid hormone receptors (class I) form functional
homodimers and include estrogen receptor (ER), pro-
gesterone receptor (PR), and androgen receptor (AR).
The class II nuclear receptors, such as retinoic acid re-
ceptor (RAR), vitamin D receptor (VDR), peroxisome*Correspondence: r.bernards@nki.nl
3 These authors contributed equally to this work.
4 Present address: Urology Department of Changzheng Hospital,
Fengyang Road 415, 200003 Shanghai, P.R. of China.proliferator-activated receptor (PPAR), and thyroid hor-
mone receptor (T3R) heterodimerize with a common
partner, retinoid X receptor (RXR) (McKenna and O’Mal-
ley, 2002).
Several coregulators control the transcriptional activ-
ity of nuclear receptors in a ligand-dependent fashion
(Xu et al., 1999). Receptors for retinoic acid and thyroid
hormone are potent repressors in the absence of li-
gand, while they function as activators of transcription
upon binding of their cognate ligands. Upon ligand
binding to these receptors, the conformational change
in the LBD induces corepressors to dislodge and co-
activators to bind, allowing transactivation (Xu et al.,
1999). NCoR and SMRT are corepressors that associate
with RAR and T3R in the absence of ligand and mediate
transrepression by recruitment of histone deacetylase
(HDAC) complexes (Alland et al., 1997; Chen and Ev-
ans, 1995; Heinzel et al., 1997; Horlein et al., 1995). In
contrast, coactivators including CBP/p300, PCAF, and
members of the p160 family (SRC1, TIF-2/GRIP1, and
ACTR/RAC3/AIB1) possess intrinsic histone acetyl-
transferase (HAT) activity and potentiate the transcrip-
tional activity of ligand bound receptors (Anzick et al.,
1997; Chen et al., 1997; Hong et al., 1997; Onate et al.,
1995; Voegel et al., 1996). The proteins RIP140 and
LCoR form a distinct group of coregulators by confer-
ring transcriptional repression to ligand bound nuclear
receptors (Cavailles et al., 1995; Fernandes et al., 2003).
These ligand-dependent coregulators recruit HDACs to
nuclear receptors to attenuate their activity.
Many ligand-dependent modulators of nuclear re-
ceptors contain nuclear receptor (NR) boxes, which are
leucine-rich motifs with an LXXLL consensus sequence
that mediates interactions with the AF-2 domain of the
nuclear receptors (Heery et al., 1997; Torchia et al.,
1997). These modulators include many coactivators,
like SRC1 (Onate et al., 1995), and the corepressors
RIP140 (Cavailles et al., 1995) and LCoR (Fernandes et
al., 2003).
Signaling through RAR and activation of RAR target
genes induce proliferation arrest, differentiation, and
apoptosis in a wide variety of cell types. Retinoids have
tumor-suppressive activity, and consequently, defects
in RAR signaling are implicated in cancers (Altucci and
Gronemeyer, 2001; Freemantle et al., 2003). In acute
promyelocytic leukemia, translocations of RARα give
rise to the PML-RARα and PLZF-RARα chimearic
genes, which results in functionally altered receptors
that act as constitutive repressors of transcription,
thereby preventing cell differentiation (Grignani et al.,
1998; He et al., 1998; Lin et al., 1998). Loss of RARβ
expression is involved in the progression of a diverse
range of solid tumors, including breast and lung carci-
nomas (Altucci and Gronemeyer, 2001; Freemantle et
al., 2003).
We describe here a function of a gene named PRAME
(preferentially expressed antigen in melanoma). PRAME
was first described as an antigen in human melanoma,
which triggers autologous cytotoxic T cell-mediated
immune responses (Ikeda et al., 1997). Interestingly,
Cell
836PRAME expression is retained in the presence of anti-
tumor T cell responses, suggesting that expression of
PRAME confers to tumor cells a selective advantage
that outweighs the CTL-mediated tumor cell killing
(Ikeda et al., 1997). This in turn suggests that PRAME
overexpression is causally involved in the tumorigenic
process. Consistent with this, the frequency of PRAME
expression in melanoma is 88% in primary melanomas
and 95% in metastases (Ikeda et al., 1997). PRAME is
not expressed in normal skin and nevi (moles) but is
highly expressed in melanomas (Haqq et al., 2005). Fur-
thermore, PRAME is overexpressed in a variety of other
human malignancies, including acute and chronic leu-
kemias, medulloblastoma, non-small cell lung carci-
noma, head and neck cancer, renal carcinoma, multiple
myeloma, and sarcomas (Boon et al., 2003; Ikeda et al.,
1997; Oberthuer et al., 2004; van Baren et al., 1998;
van’t Veer et al., 2002). Importantly, high PRAME ex-
pression is an independent prognostic marker of poor
clinical outcome in breast cancer and neuroblastoma
(Oberthuer et al., 2004; van’t Veer et al., 2002). High
PRAME expression inversely correlates with recur-
rence-free survival (no metastases) and overall survival
in breast cancer (van’t Veer et al., 2002). As expression
of PRAME is low or absent in almost all normal adult
tissues except for testis (Ikeda et al., 1997), its specific
selection in a variety of tumor types has remained un-
explained, as no function for PRAME has been de-
scribed to date. In the current study, we addressed the
function of PRAME and found an unexpected role for
PRAME in suppression of retinoic acid signaling.
Results
PRAME Is a Transcriptional Repressor of RAR
To address the function of PRAME in oncogenesis, we
searched for conserved motifs and functional domains
in the protein. We found that PRAME contains, apart
from a nuclear localization signal, seven putative
nuclear receptor (NR) boxes, having the LXXLL consen-
sus sequence (Heery et al., 1997; Torchia et al., 1997;
Figure 1A). The presence of NR boxes suggested that
PRAME could function as a modulator of nuclear re-
ceptor signaling. To test if PRAME can act as a tran-
scriptional coactivator or corepressor, a full-length
PRAME cDNA was fused to a heterologous DNA bind-
ing domain (DBD) of the yeast transcription factor Gal4
and cotransfected with a Gal4-luciferase reporter. Gal4-
PRAME caused a dose-dependent inhibition of reporter
gene expression, whereas free PRAME had no effect
on the Gal4 promoter (data not shown), indicating that
PRAME mediates transcriptional repression (Figure 1B).
To investigate if PRAME affected transactivation medi-
ated by nuclear receptors, we used luciferase reporter
constructs for several class I and class II receptors.
These experiments revealed that PRAME inhibited RA-
induced activation of a reporter gene driven by retinoic
acid-responsive elements (RARE-luciferase) in a con-
centration-dependent manner (Figure 1C). PRAME co-
transfection did not affect estrogen receptor (ER)-
driven reporter activation (Figure 1D) nor activation by
the other class I nuclear receptors tested, such as the
progesterone receptor (PR, Figure 1E) or androgen re-
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rceptor (data not shown). Moreover, there was no effectf PRAME on ligand-induced transactivation of the
lass II receptor PPARγ (Figure 1F), indicating that
RAME is not a general inhibitor of class II nuclear recep-
ors. To test if PRAME affected RAR signaling through its
eterodimerization partner RXRα, PRAME was cotrans-
ected with RXRα and a RXRα-responsive reporter. Figure
G shows that PRAME did not affect activation of RXRα
y its ligand, 9-cis-RA. To investigate if PRAME can act
n all RAR isoforms, we cotransfected PRAME together
ith RARβ or RARγ and found that PRAME also inhib-
ted signaling through these two RAR isoforms (Figure
H). These experiments indicate that PRAME is selec-
ive in its functional interactions with nuclear receptors
nd, of the nuclear receptors tested, only interfered
ith RAR transactivation (Figures 1C–1H). Similarly,
RAME repressed RAR signaling in B16 mouse mela-
oma cells (Figure S1 available with this article online).
owever, these data do not exclude the possibility that
RAME can modulate the activity of other nuclear re-
eptors.
nteraction of PRAME with RAR In Vitro
nd In Vivo
he presence of putative NR boxes in PRAME suggests
hat PRAME can form direct physical complexes with
uclear receptors to modulate receptor function (Heery
t al., 1997; Torchia et al., 1997). Interactions of PRAME
ith nuclear receptors were demonstrated in GST pull-
own experiments using GST fusions of the LBDs of
ARα, RXRα, and ERα and in vitro-translated PRAME.
he C terminus of PRAME (416–509) associated with
ST-RARα-LBD in the presence of ligand but did not
ind to GST-RXRα-LBD and GST-ERα (Figure 2A). Con-
urrently, heterodimerization between GST-RXRα and
ARα was shown and ERα was bound to GST-ERα in
he presence of estradiol, indicating proper folding of
he expressed proteins. Conversely, a GST-PRAME
416–509) fusion protein interacted with in vitro-trans-
ated RARα only in the presence of all-trans-RA, but
o RXRα was bound to this fragment of PRAME in the
resence or absence of its ligand 9-cis-RA (Figure 2B).
Interaction of PRAME with RAR was further probed
y mammalian two-hybrid analysis. We used VP16 trans-
ctivation domain (TAD) fusion proteins with RARα-LBD
r RXRα-LBD together with a Gal4-DBD-PRAME (416–
09) and a Gal4-luciferase reporter gene as a readout
or interaction (Figure 2C). Association of Gal4-PRAME
416–509) with VP16-RARα was apparent from the two-
ybrid signal when both fusion proteins were coex-
ressed in the presence of ligand, but there was no
eporter activation by either construct alone (Figure
D). Consistent with the GST pull-down assay, no in-
eraction was found between Gal4-PRAME (416–509)
nd VP16-RXRα, again indicating that the C terminus
f PRAME interacts with the LBD of RARα but not with
he LBD of RXRα (Figure 2D). Moreover, coexpression
f Gal4-PRAME (416–509) and VP16-RXRα resulted in
ctivation of transcription only in the presence of both
ARα and RA, demonstrating a requirement for RAR in
he effects mediated by PRAME (Figure 2D). In a mam-
alian two-hybrid assay, Gal4-RARα interacted with
P16-RXRα in the presence of PRAME, reflecting that
eceptor heterodimerization was not hampered by
PRAME in vivo (Figure S1). Together, these data sug-
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naling
(A) Schematic representation of PRAME.
Amino acid residue numbers of the seven
putative NR boxes (LXXLL motifs) and adja-
cent amino acids are indicated.
(B) PRAME confers transcriptional repres-
sion to a reporter construct. A Gal4-PRAME
fusion protein inhibits transcription from a
Gal4-luciferase reporter in HEK293 cells.
(C–G) PRAME represses RAR-dependent
transactivation. The effects of PRAME on
nuclear receptor transactivation were tested
in cotransfection experiments using expres-
sion vectors for the receptors and luciferase
reporters for the nuclear receptors RARα
(RARE-luc, where RARE is for RA-responsive
element), estrogen receptor (ERE-luc), pro-
gesterone receptor (PRE-luc), PPARγ (PPRE-
luc), and RXRα (DR1-luc). Cells were treated
with 1 M of hormones (RA, all-trans RA; E2,
estradiol; P, progesterone; T, Troglitazone;
9-cis-RA) for 24 hr prior to measurements.
(H) PRAME represses signaling through
RARβ and RARγ. MCF7 cells were cotrans-
fected with expression vectors for RARβ,
RARγ, and a specific shRNA to repress en-
dogenous RARα to measure the effects of
PRAME on RARβ and RARγ signaling.gest that the association between RAR and PRAME is
the result of a direct and ligand-dependent physical in-
teraction.
To ask if PRAME binds RAR in vivo, we stably ex-
pressed a TAP-tagged (Rigaut et al., 1999) PRAME in
mouse embryonic fibroblasts (MEFs) to levels compa-
rable to those of endogenous PRAME in the human
melanoma cell lines SK23 and A375 (Figure 3A). Endog-
enous RARα coimmunoprecipitated with TAP-PRAME,
indicating that PRAME and RARα form a complex at
protein concentrations seen in human tumor cell lines
(Figure 3B). Formation of the PRAME-RAR complex in
vivo was also dependent on the presence of RA, show-
ing that PRAME, like other proteins that harbor NR box
motifs, forms a ligand-regulated complex with RAR
(Figure 3C).
PRAME Interacts with RAR through a Nuclear
Receptor Box Motif
The presence of NR boxes in PRAME suggests that the
interaction between PRAME and RARα takes place via
one or more of these motifs. To test if the NR boxes ofPRAME are required for binding to RAR and inhibition
of RAR signaling, point mutations were introduced in
each of the seven LXXLL motifs in PRAME by changing
conserved leucine (L) residues into valines (V). The re-
sulting PRAME mutants were named after the respec-
tive NR boxes that were mutated. One additional mu-
tant was made in which all seven LXXLL motifs were
mutated, referred to as PRAME-LXXLL. Six out of
seven PRAME single NR box mutants inhibited RAR
signaling to a similar extent as wild-type PRAME, ex-
cept for the PRAME-LREVV mutant (Figure 3E). This
mutant was as defective in repressing RAR signaling as
the PRAME mutant in which all seven NR boxes were
mutated (Figure 3E). Consistent with this observation,
endogenous RARα failed to coimmunoprecipitate with
a TAP-PRAME-LREVV mutant protein (Figure 3D). Gal4-
PRAME-LREVV inhibited reporter activity to a similar
extent as Gal4-PRAME, indicating that repression was
not affected by the LREVV mutation (Figure S1). In a
mammalian two-hybrid assay, Gal4-PRAME (416–509)
containing the wild-type LRELL NR box interacted with
VP16-RARα, but introduction of the LREVV mutation in
Cell
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RARα
(A) In vitro binding of PRAME to RARα. GST
pull-down assay showing the interaction of
in vitro-translated 35S-labeled PRAME (416–
509) with GST-RARα-LBD but not GST-
RXRα-LBD and GST-ERα (left panel) in the
presence of ligand (1 M all-trans-RA, 9-cis-
RA, or estradiol, respectively). The same
protein preparations were used to demon-
strate interactions between GST-RXRα-LBD
and in vitro-translated RARα (middle panel)
and GST-ERα and in vitro-translated ERα
(right panel) in the presence of ligand (1 M
all-trans-RA or estradiol, respectively).
(B) Ligand-dependent interaction of PRAME
and RARα. GST pull-down assay showing a
ligand-dependent interaction of in vitro-
translated 35S-labeled RARα but not RXRα
with GST-PRAME (416–509). Ligand (1 M)
was all-trans-RA for RARα and 9-cis-RA for
RXRα.
(C) Schematic representation of the mamma-
lian two-hybrid assays in Figures 2D and 3F
(DBD, DNA binding domain; LBD, ligand bind-
ing domain; TAD, transactivation domain).
(D) Mammalian two-hybrid assay for binding
of PRAME to RARα. Coexpression of Gal4-
PRAME (416–509) with VP16-RARα-LBD but
not VP16-RXRα-LBD results in activation
of a Gal4-driven luciferase reporter in the
presence of ligand (1 M all-trans-RA and
9-cis-RA).PRAME disrupted the association (Figure 3F). Taken to-
gether, these data suggest that an intact LRELL motif
in PRAME is required for binding to RARα and repres-
sion of RAR signaling.
PRAME Inhibits RA-Induced Differentiation,
Proliferation Arrest, and Apoptosis
RA induces proliferation arrest, differentiation, and apo-
ptosis in many cell types, including F9 mouse embry-
onic carcinoma cells (Strickland and Mahdavi, 1978).
We asked if PRAME expression affected the RA-induced
differentiation of F9 cells toward parietal endoderm. F9
cells were stably transfected with PRAME, PRAME-
LREVV, or control vector and differentiated in 10−7M RA.
In the absence of RA, the morphology of all transfected
cells was the same as that of parental F9 cells (Figure
4Aa–4Ac). F9 cells expressing PRAME were resistant
to RA-induced morphological differentiation, whereas
PRAME-LREVV and vector control transfected cells un-
derwent differentiation (Figure 4Ad–4Af). Undifferenti-
ated F9 cells express Stage-Specific Embryonic Anti-
gen-1 (SSEA-1), which is a marker of stem cells and
embryonic carcinoma cells (Solter and Knowles, 1978).
F9 cells were stained for SSEA-1 before and after treat-
ment with RA. In agreement with earlier studies (Solter
and Knowles, 1978), we found that SSEA-1 expression
was lost upon differentiation. Vector-control and PRAME-
LREVV F9 cells completely lost SSEA-1 expression,
whereas a significant fraction of PRAME F9 cells re-
tained expression of the marker (Figure S2). Parietal en-
doderm-like F9 cells show coordinated expression and
secretion of basement-membrane components, includ-
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uing laminin-1 and collagen IV (Strickland et al., 1980).onditioned medium of F9 cells contained laminin-1
nly after RA treatment, but PRAME-expressing F9 cells
ecreted less laminin-1 than vector and PRAME-LREVV
9 cells (Figure S2). F9 cells expressing PRAME showed
nhanced proliferation compared to PRAME-LREVV
nd vector controls in standard culture medium (which
ontains trace amounts of RA), and this difference was
ore pronounced when the culture medium was sup-
lemented with exogenous RA (Figure 4C). The RARb
nd the CDK-inhibitor p21cip1 genes are RA inducible
nd contain RA-responsive elements in their respective
romoters (de The et al., 1990; Liu et al., 1996). Consis-
ent with this, endogenous RARβ and p21 protein ex-
ression levels are induced by RA in vector control and
RAME-LREVV-transfected F9 cells but not in PRAME-
ransfected F9 derivatives (Figure 4B). Furthermore,
RAME inhibited RA-induced activation of a RARβ2
romoter-luciferase reporter (R140-luc) but did not af-
ect a RARβ2 reporter with a mutated RARE (M3M7-luc)
Figure 4D). PRAME-LREVV failed to repress the RARβ2
romoter reporter, consistent with a requirement for
inding of PRAME to RARα through an intact LRELL
otif to repress RARα transactivation (Figure 4D). Simi-
arly, a p21 promoter-luciferase reporter was activated
y RA, and this activation was suppressed by PRAME,
ut not by PRAME-LREVV expression (Figure 4E). Apart
rom differentiating, a fraction of F9 cells treated with
A dies by apoptosis (Atencia et al., 1994). PRAME ex-
ression in F9 cells conferred resistance to RA-induced
poptosis as activated, cleaved caspase 3 was apparent
n vector controls but not in PRAME transfectants (Fig-
re 4F). However, apoptosis was induced by UV irradia-tion in both PRAME and vector control F9 cells, indicat-
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through an LXXLL Motif
(A) Comparison of TAP-PRAME expression
levels in MEFs to endogenous PRAME pro-
tein levels in human melanoma cell lines
A375 and SK23. Cell extracts were analyzed
by Western blotting using antibodies against
PRAME and CDK4.
(B) Association of PRAME and RARα in
MEFs. TAP and TAP-PRAME were immuno-
precipitated (IP) (using IgG beads, indicated
as anti-TAP) and immunocomplexes were
analyzed by Western blotting with anti-
PRAME and anti-RARα antibodies.
(C) Ligand-dependent binding of PRAME to
RARα. TAP-PRAME was immunoprecipitated
as in (B) in the absence or presence of RA.
(D) Immunoprecipitation of RARα and
PRAME or PRAME-LREVV. TAP-PRAME and
TAP-PRAME-LREVV were immunoprecipi-
tated as in (B) and precipitates were immu-
noblotted for PRAME and RARα.
(E) Effects of PRAME NR box mutants on RAR
signaling. MEFs were transfected with RARE-
luc and PRAME or PRAME NR box mutants
(see text for description) and treated with RA.
In each PRAME mutant, one LXXLL motif was
changed, except for PRAME-LXXLL, which
contained mutations in all seven NR boxes.
(F) Mammalian two-hybrid assay for binding
of PRAME or PRAME-LREVV to RARα. The
following constructs: Gal4-PRAME-LRELL
(416–509) or Gal4-PRAME-LREVV (416–509)
and VP16-RARα-LBD were coexpressed in
the presence of RA.ing that PRAME is not a general inhibitor of apoptosis
(Figure 4F). Apoptosis was further confirmed by posi-
tive Annexin V staining in dying cells (Figure S2). We
conclude that PRAME expression confers resistance to
RA-induced proliferation arrest, differentiation, and
apoptosis by repressing the expression of bona fide en-
dogenous RAR target genes.
PRAME Interacts with Polycomb Group EZH2
to Repress RAR Signaling
Transcriptional repression often involves recruitment of
protein complexes harboring one or more histone de-
acetylases (HDACs) (Kouzarides, 1999). To address the
mechanism of repression by PRAME, we asked if re-
pression by PRAME is inhibited by treatment of cells
with the HDAC inhibitor trichostatin A (TSA). Figure 5A
shows that TSA did not affect transcriptional repression
by PRAME, indicating that repression is mostly HDAC
independent, whereas repression by BS69, an HDAC-
dependent repressor (Masselink and Bernards, 2000),
was attenuated by TSA treatment (Figure 5A). Instead,
we considered polycomb group (PcG) proteins as can-
didates for transcriptional repression by PRAME for
two reasons. First, PcG proteins act in large complexes
that are involved in the initiation and maintenance of
heritable gene silencing, and PcG silencing is mostly
HDAC independent (reviewed in Jacobs and van Lohui-zen, 2002). Second, gene expression profiling of a
series of human Wilms’ tumors shows that PRAME ex-
pression closely parallels expression of EZH2 (M. Eil-
ers, personal communication), a PcG protein associ-
ated with malignant progression in breast and prostate
cancer (Kleer et al., 2003; Varambally et al., 2002). To
test if a complex containing PRAME and EZH2 exists,
human HEK293 cells were transfected with expression
plasmids for both proteins. In a subsequent coimmuno-
precipitation experiment, Myc-tagged EZH2 was found
as a binding partner of Flag-tagged PRAME, suggest-
ing that the proteins do interact, whereas no immuno-
precipitation of either protein was observed by control
IgG (Figure 5C). To test the functional relevance of the
PRAME-EZH2 complex in repression by PRAME, en-
dogenous EZH2 was inhibited using RNA interference.
The sequence-specific short hairpin RNA (shRNA) vec-
tor pRS-EZH2 reduced endogenous EZH2 protein
levels after transfection into human cells but did not
affect the endogenous levels of another PcG protein
EED (Figure 5D). EZH2 knockdown inhibited transcrip-
tional repression by the Gal4-PRAME fusion protein,
suggesting that PRAME requires this PcG protein to
confer repression (Figure 5B).
To test the functional relevance of endogenous PRAME
and EZH2 in repression of RAR signaling, endogenous
PRAME and EZH2 were inhibited in A375 melanoma
Cell
840Figure 4. PRAME Is a Repressor of RA-Induced Differentiation, Growth Arrest, and Apoptosis
(A) Effects of PRAME expression on differentiation of F9 embryonic carcinoma cells. F9 cells were stably transfected with vector, PRAME, or
PRAME-LREVV (a–c) and differentiated in 10−7 M RA (d–f, 200× magnification).
(B) PRAME inhibits RA-induced gene expression. Cells as in (A) were analyzed by Western blotting for PRAME, RARβ, p21, and CDK4
(loading control).
(C) Effects of PRAME on F9 cell proliferation arrest induced by RA. Proliferation curve according to the 3T3 protocol of F9 cells as in (A) in
the absence and presence of RA.
(D and E) PRAME represses transcription from the RARβ and p21 promoters. (D) MEFs were cotransfected with a RARβ2-promoter-luciferase
(R140-luc) or a RARβ2-luciferase with a mutated RARE (M3M7-luc) and either PRAME, PRAME-LREVV, or empty vector and treated with RA.
(E) B16 melanoma cells were transfected with a p21-promoter luciferase construct and either PRAME, PRAME-LREVV, or empty vector and
treated with RA.
(F) PRAME inhibits RA-induced apoptosis. F9 cells with PRAME or empty vector transfectants were immunoblotted for cleaved caspase 3. A
doublet of 17, 19 kDa caspase 3 fragments is visible after treatment of vector control cells with RA. F9 cells were irradiated with UV light (100
J/m2) and were immunoblotted for cleaved caspase 3 10 hr after irradiation. Cleaved caspase 3 is visible as a 17 kDa band in lysates of cells
after treatment with UV light (l.c., loading control).cells (which express high levels of PRAME, see below)
using specific shRNA vectors, pRS-PRAME (Figure 6B)
and pRS-EZH2 (Figure 5D), respectively (Brummelkamp
e
t
lt al., 2002a). After knockdown, the responsiveness of
he cells to RA treatment was tested using a RARE-
uciferase or RARβ-luciferase reporter gene. Knock-
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(A) Transcriptional repression by PRAME is
insensitive to HDAC inhibitors. HEK293 cells
were transfected with Gal4-PRAME or Gal4-
BS69 fusions and a Gal4-luciferase reporter
and treated with 1 M TSA.
(B) Transcriptional repression by PRAME is
mediated by EZH2. HEK293 cells were co-
transfected with Gal4-PRAME, a Gal4-lucif-
erase reporter, and pRS-EZH2 or pRS-p21,
which was used as a shRNA control vector.
(C) PRAME associates with EZH2. HEK293
cells were transfected with Flag-PRAME and
Myc-EZH2 as indicated and immunoprecipi-
tated (IP) using anti-Flag antibodies. Immu-
noprecipitates were analyzed by Western
blotting (WB) using anti-Flag and anti-Myc
antibodies.
(D) Specific RNAi vectors efficiently de-
crease the expression levels of PcG genes
EZH2 and EED. A375 cells were transfected
with shRNA vectors against EZH2 and EED
(pRS-EZH2 and pRS-EED), and protein levels
were analyzed by Western blotting. Two iso-
forms of EED are visible.
(E) Interference with PcG proteins enhances
RAR signaling. A375 cells were transfected
with the RARE-luciferase reporter and with
the indicated constructs. pRS-PRAME is
a shRNA vector to reduce endogenous
PRAME levels in A375 cells (see Figure 6B)
and pRS-p21 was used as a shRNA control
vector.
(F) p21 is induced after EZH2 knockdown.
A375 melanoma cells were transfected with
pRS-PRAME or pRS-EZH2 in the presence
of RA and immunoblotted for p21 and CDK4
(loading control).
(G) Knockdown of EZH2 enhances RARβ2
promoter activity in A375 cells.down of endogenous PRAME resulted in enhanced
RAR signaling, as detailed below, and overexpression
of PRAME-LREVV had a similar effect (Figure 5E).
Knockdown of EZH2 was effective in restoring RAR sig-
naling (Figures 5E and 5F). EZH2 contains a conserved
SET domain, which specifies histone methyl transfer-
ase (HMTase) activity (Jenuwein et al., 1998). Ectopic
expression of a point mutant EZH2 having a HMTase-
deficient SET domain (H694L) (Kuzmichev et al., 2002)
also restored RAR signaling, indicating that an intact
SET domain in EZH2 is required for repression of RAR
signaling by PRAME (Figure 5E). EZH2 acts in a multi-
protein PcG complex, named PRC2 (Kuzmichev et al.,
2002), that also contains the protein EED (Sewalt et al.,
1998). We found that knockdown of EED through RNA
interference (Figure 5D) also restored RA responsive-
ness, suggesting that EED, like EZH2, is required for
repression of RAR signaling (Figure 5E). Finally, knock-
down of EZH2 restored RA-induced expression of the
RA target gene p21cip1 and activated the RARβ pro-
moter (Figures 5F and 5G). Together, these data sug-
gest a role for PcG proteins in mediating the inhibition
of RAR signaling by PRAME.
Knockdown of PRAME Restores Sensitivity to RA
Human melanomas often have defects in RAR signaling
(Demary et al., 2001; van der Leede et al., 1993), andPRAME is expressed in nearly all melanomas (Ikeda et
al., 1997) (Figure 6A), raising the possibility that PRAME
expression is responsible for their resistance to RA. To
test this, we inhibited PRAME expression in human
melanoma through RNA interference. Transfection of
A375 melanoma cells with a PRAME-specific shRNA
vector (pRS-PRAME) caused a significant decrease in
levels of endogenous PRAME protein (Figure 6B).
Knockdown of PRAME enhanced RAR signaling in
A375, FM6, and SK23 human melanoma cells, which
are all relatively insensitive to RA (Figure 6C). Similarly,
knockdown of PRAME increased the response to RA in
human breast cancer cells MCF7 and 1.6.2. (Figure 6D).
Together, these data support the notion that PRAME
expression confers resistance to RA.
To assess the effect of PRAME knockdown on
cell proliferation, we generated stable derivatives of
A375 melanoma having shRNA-mediated knockdown
of PRAME expression (Figure 6F). These A375-PRAMEKD
cells were cultured for 15 days according to the 3T3
protocol in the presence and absence of exogenous RA
(Figure 6E). PRAMEKD cells showed decreased prolifer-
ation rates in standard culture medium (having trace
amounts of RA) compared to vector control A375 cells;
the decreased rates were more pronounced when cul-
tured in the presence of supplemented RA (Figure 6E).
Consistent with the notion that PRAME knockdown re-
Cell
842Figure 6. PRAME Knockdown Restores RAR Signaling
(A) PRAME is expressed in human melanoma cells. Western analysis of endogenous PRAME in extracts from human melanoma cells lines.
MEFs transfected with PRAME were used as a positive control.
(B) A PRAME RNAi plasmid efficiently knocked down PRAME expression. A375 melanoma cells were transfected with a specific shRNA
vector, pRS-PRAME, and were compared to cells transfected with empty vector (pRS) by immunoblotting of cell extracts for PRAME and
CDK4 (loading control).
(C and D) PRAME knockdown by RNAi results in enhanced RAR signaling. (C) A375, FM6, and SK23 human melanoma cells were cotrans-
fected with the RARE-luciferase reporter and either pRS-PRAME or empty vector (pRS) and treated with RA.
(D) MCF7 and 1.6.2. human breast cancer cells were transfected and treated as in (C).
(E) PRAME RNAi restores sensitivity to RA in melanoma. A375 cells were stably transfected with pRS-PRAME to generate A375-PRAMEKD
cells. Proliferation curve according to the 3T3 protocol of A375-PRAMEKD cells and vector control cells in the absence and presence of RA.
(F) Derepression of RAR target genes after PRAME knockdown. A375-PRAMEKD cells and control A375 cells were analyzed by Western
blotting for protein levels of PRAME, RARα, p21, and RARβ (l.c., loading control).
(G) RA induces p21 in A375-PRAMEKD cells. Cells as in (F) were treated with RA and immunoblotted for p21 and CDK2.
(H) PRAME is located at the RARβ promoter. Chromatin immunoprecipitation (ChIP) analysis demonstrates the promoter occupancy by
endogenous PRAME on the RARβ promoter in A375 melanoma cells treated with RA. Thirty-five cycles of PCR amplification were used to
show promoter occupancy (upper panel). Quantitative PCR showed specific enrichment for the RARβ promoter in the PRAME immunoprecipi-
tate compared to preimmune serum after normalization to GAPDH, which was used as an internal ChIP control (lower panel).
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843stores RAR signaling, the known RA target genes RARb
and p21CIP1 (de The et al., 1990; Liu et al., 1996) were
significantly upregulated in PRAMEKD cells (Figure 6F).
Induction of these genes was further enhanced by ex-
posure to exogenous RA (Figure 6G and data not
shown).
RARα is degraded by the proteasome following treat-
ment of cells with RA (Zhu et al., 1999), and in agree-
ment with the notion that RAR signaling is activated in
PRAMEKD cells, RARα protein levels were decreased in
PRAMEKD cells (Figure 6F).
The specific targeting of PRAME mRNA by shRNA-
mediated RNAi was further investigated by introduction
of a PRAME silent mutant, indicated as PRAMEM,
which contains three silent point mutations in the 21-
mer RNAi target sequence. Hence, this mutant is insen-
sitive to pRS-PRAME (Figure S3). Cotransfection of
PRAMEM restored the insensitivity of A375 cells to RAR
signaling in the presence of pRS-PRAME (Figure S3).
Introduction of PRAMEM into PRAMEKD cells rescued
the growth defects in these cells and partially restored
their resistance to RA-mediated growth arrest (Figure
S3). In addition, the levels of RARβ and p21 proteins
in these cells were suppressed compared to PRAMEKD
cells, consistent with a role for PRAMEM in inhibition of
RAR target gene expression in PRAMEKD cells (Figure
S3). We conclude that the observed effects of the pRS-
PRAME vector are due to specific effects on the in-
tended target and cannot be explained by off-target ef-
fects of the shRNA vector.
To further confirm that PRAME is part of the RAR
transcription complex, we examined the recruitment of
PRAME to the promoters of endogenous RA-respon-
sive genes. We used A375 melanoma cells, which were
cultured in the presence of RA and determined the
status of the endogenous transcription complexes
present on the RARβ promoter using chromatin immu-
noprecipitation (ChIP). The presence of this promoter
in the chromatin immunoprecipitates was analyzed by
quantitative PCR using a specific pair of primers span-
ning the retinoic acid-responsive region in the RARβ
promoter. As shown in Figure 6H, immunoprecipitation
of endogenous PRAME resulted in enrichment of the
RARβ promoter in the precipitates relative to a preim-
mune serum from the same rabbit, indicating occu-
pancy by PRAME of this promoter. These data show
that PRAME is located at a genuine RAR target gene
promoter and that it acts on the chromatin template to
block RAR-RXR-dependent gene transcription.
Knockdown of PRAME and Treatment with RA
Inhibit Melanoma Growth In Vivo
To examine the role of PRAME in RA responsiveness
in vivo, we used a human melanoma xenograft model.
Nude mice were subcutaneously transplanted with par-
ental A375 into one flank and A375-PRAMEKD cells in
the opposite flank and the mice were treated orally
daily with either 5 mg/kg RA or vehicle only, while tumor
volumes were measured weekly. Tumor growth was se-
verely retarded by RA treatment in PRAMEKD melano-
mas but not in parental A375 melanomas that grew in
a different anatomical location in the same mice (Fig-ures 7A and 7B). Together, these data suggest that
PRAME functions as a negative regulator of RAR sig-
naling, and its overexpression may contribute to RA un-
responsiveness of human melanomas.
Discussion
The human tumor antigen PRAME is frequently overex-
pressed in human cancer, but its function has remained
obscure. In the current study we identify PRAME as a
ligand-dependent corepressor of retinoic acid receptor
signaling. PRAME interacts only with ligand bound RAR
(holo-receptor) through a nuclear receptor (NR) box and
attenuates RAR signaling in the presence of agonist in
a Polycomb-dependent fashion. In this respect, PRAME
is distinct from the major nuclear receptor corepressors
identified thus far. For instance, the established nuclear
receptor corepressors N-CoR and SMRT interact with
apo-receptors in the absence of ligand and their in-
teraction is lost upon ligand binding of the receptor (Xu
et al., 1999). PRAME resembles the proteins RIP140
(Cavailles et al., 1995) and LCoR (Fernandes et al.,
2003), which also are ligand-dependent corepressors
of nuclear receptors. However, LCoR and RIP140 act
on a variety of class I and class II nuclear receptors,
repress transcription in a HDAC-dependent fashion, are
widely expressed in normal tissues, and do not appear
to be overexpressed in cancer. In contrast, PRAME ex-
pression is absent in adult tissues and is selected for
during oncogenesis, and PRAME requires Polycomb
proteins for repression and appears to act with a con-
siderable degree of specificity on RAR.
We provide several lines of evidence that PRAME
functions to negatively regulate cellular responses to
retinoids. First, PRAME expression in RA-sensitive F9
mouse embryonic carcinoma cells inhibited the physio-
logical consequences of RA treatment, notably cell-
cycle arrest, differentiation, and apoptosis. Consistent
with this, PRAME inhibits RA target genes p21 and
RARβ, thus interfering with the transcriptional re-
sponses to RA. Second, PRAME is frequently overex-
pressed in human melanomas (Ikeda et al., 1997),
which are also frequently resistant to RA (Demary et al.,
2001; van der Leede et al., 1993). A causal relationship
between these two apparently unrelated observations
was revealed by our demonstration that knockdown of
PRAME levels in melanoma by RNA interference re-
sulted in restoration of the sensitivity to the antiprolifer-
ative effects of RA, in greatly enhanced RAR signaling
and induction of RA target genes p21 and RARβ. Impor-
tantly, in a mouse xenograft experiment, melanoma
cells having PRAME knockdown regained sensitivity to
the antiproliferative effects of RA treatment, again high-
lighting the inverse relationship between PRAME ex-
pression and sensitivity to RA in an animal model.
Unlike the established nuclear receptor corepres-
sors, which recruit HDAC complexes of varying compo-
sition, repression by PRAME is relatively insensitive to
treatment with HDAC inhibitors, suggesting an HDAC-
independent mechanism. Our data indicate that PRAME
interacts with the PcG protein EZH2 in vivo and that
EZH2 is involved in transcriptional repression by
PRAME. Significantly, knockdown of EZH2 levels re-
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844Figure 7. PRAME Knockdown Restores RA-
Induced Growth Arrest In Vivo
(A) Xenograft of PRAME RNAi melanoma
cells is sensitive to RA treatment. A375-
PRAMEKD cells and control A375 cells were
injected in the right and left flanks of nude
mice, respectively, and mice were treated
orally with 5 mg/kg RA daily. Tumor growth
was measured weekly.
(B) Dissected tumors from the experiment
in (A).
(C) Model for PRAME-mediated repression
of RAR signaling. (I) In the absence of ligand,
RARα is a repressor of gene transcription,
but upon binding of RA, target genes are ex-
pressed to induce cell-cycle arrest, differen-
tiation, and apoptosis. (II) In promyelocytic
leukemia (APL), the PML-RARα and PLZF-
RARα translocations result in functionally
altered receptors, which are transcriptional
repressors under physiologic RA concentra-
tions, preventing myelocyte differentiation.
The PML and PLZF parts of the fusion recep-
tors recruit repressor complexes containing
HDAC. (III) PRAME binds RAR in the pres-
ence of RA to block target gene expression,
which requires PcG proteins including EZH2.
The resulting constitutive inhibition of RAR
signaling resembles the repression as seen
in APL (II). RARE: retinoic acid-responsive el-
ement.stored RAR signaling in melanoma cells, suggesting a
role for PcG proteins in regulation of the effects of RA
through interaction with PRAME. PcG proteins act in
large, multimeric complexes and mediate heritable
gene silencing through chromatin remodeling (Jacobs
and van Lohuizen, 2002). Dysregulation of PcG proteins
has been implicated in cancer, and overexpression and
amplification of EZH2 are prognostic for progression to
metastatic disease in breast and prostate carcinoma
(Kleer et al., 2003; Varambally et al., 2002). Inhibition of
RAR transactivation by PcG proteins has been reported
in embryonic development, but not in adult tissues. The
mouse homolog of the Drosophila Polycomb gene,
M33, is thought to antagonize the RAR pathway and
to function in the establishment of the early temporal
sequence of Hox gene activation in the embryo (Bel-
Vialar et al., 2000). From studies in M33-deficient mice,
it has been proposed that M33 may play a role in defin-
ing access to retinoic acid response elements localized
in the regulatory regions of several Hox genes (Core et
al., 1997).
Cellular transformation, tumor development, and can-
cer progression are affected by many pathways, and RAR
signaling is one of the pathways which can be disturbed
in malignant disease. The effects of retinoids are tumor
suppressive in a wide variety of tissues, where binding of
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hA to RAR induces a transcriptional response resulting in
ell-cycle arrest, differentiation, and apoptosis (Altucci
nd Gronemeyer, 2001) (Figure 7C). Consistent with
his, loss of RARβ expression is correlated with tumor
rogression in solid tumors, and genetic evidence indi-
ates that RARβ is involved in tumorigenesis. Introduc-
ion of exogenous RARβ in several RA-unresponsive
umor cell lines can restore their growth-inhibitory
esponses to RA (Altucci and Gronemeyer, 2001). Per-
urbations of RARα function cause promyelocytic leuke-
ia, where the PML-RARα and PLZF-RARα translocation
roducts recruit HDAC/Sin3A-containing repressor com-
lexes, thereby preventing normal RARα target gene
xpression and promyelocyte differentiation (Grignani
t al., 1998; He et al., 1998; Lin et al., 1998; Figure 7C).
ur data indicate that PRAME interacts with RAR in a
igand-dependent manner and inhibits RAR-dependent
ransactivation through interaction with PcG com-
lexes. We propose that PRAME expression in tumor
ells renders these cells resistant to normal retinoid ac-
ion (Figure 7C). In this respect, PRAME overexpression
henocopies the PML-RARα and PLZF-RARα translo-
ations in that both interfere with RAR signaling under
hysiological concentrations of RA. Melanoma cells
nd other tumor cells that overexpress PRAME may
ave a selective advantage over PRAME-negative cells,
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845which would provide an explanation for why PRAME
expression is positively selected during oncogenesis,
even though its presence elicits a cytotoxic T cell-medi-
ated immune response (Ikeda et al., 1997). Since
PRAME is a marker of poor outcome in breast cancer
and neuroblastoma (Oberthuer et al., 2004; van’t Veer
et al., 2002), it is likely that PRAME expression contrib-
utes to tumor progression rather than the early stages
of oncogenic transformation. Thus, our data suggest
that PRAME overexpression represents a novel mecha-
nism by which tumor cells can escape from tumor-sup-
pressive RAR signaling.
Experimental Procedures
Plasmids, Reagents, and Antibodies
The PRAME NR box mutants, the PRAMEM silent mutant, and EZH2
(H694L) were made using the QuikChange Site-Mutagenesis kit
(Stratagene). pRS-PRAME was generated by ligating synthetic oli-
gonucleotides against the target sequence GGTGCCTGTGATG
AATTGTTC into pRETRO-SUPER as described (Brummelkamp et
al., 2002b). PRAMEM contains three silent mutations in the shRNA
target sequence resulting in GGCGCCTGCGACGAATTGTTC. RA-
responsive luciferase constructs were kindly provided by Dr. H.
Stunnenberg (Nijmegen, The Netherlands) and PcG expression and
shRNA vectors were kind gifts of Dr. M. van Lohuizen (Amsterdam,
The Netherlands). The RNAi target sequence in EED was AAGCAC
TATGTTGGCCATGGA, the target sequence in EZH2 was AAG
ACTCTGAATGCAGTTGCT, and the target sequence in RARα was
GCCTTGCTTTGTCTGTCAG. PRAME antisera and affinity-purified
antibodies were a generous gift from Dr. P. Coulie (Brussels, Bel-
gium) and were generated by immunizing rabbits with peptides
FPEPEAAQPMTKKRKVDG (AH-151/serum 440) and CGDRTFYD
PEPIL (AH-152/serum 442). The anti-EZH2 mouse monoclonal anti-
serum was a kind gift from Dr. A. Otte (Amsterdam, The Nether-
lands). All-trans-retinoic acid (RA), 9-cis-retinoic acid (9-cis-RA),
β-estradiol, progesterone, TSA, and Flag (M2) antibody were from
Sigma, and Troglitazone was from Alexis Biochemicals. Antibodies
against RARα (C-20), RARβ (C-19), p21 (F5), Myc (9E10), CDK4
(C-22), and CDK2 (H-298) were from Santa Cruz Biotechnology,
anti-EED was from Transduction laboratories, anti-cleaved cas-
pase-3 (Asp 175) was from Cell Signaling, the SSEA-1 antibody
(MC-480) was from R&D Systems, and anti-Laminin-1 was from
Monosan (EHS-Laminin, PS040).
Cell Cultures and Transfections
All cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS). Transfec-
tions were carried out using the Lipofectamine2000 reagent (Invitro-
gen), except for MCF7, U2OS, HEK293, and MEFs, which were
transfected using calcium phosphate precipitation. Hormone-
based reporter assays were done in DMEM supplemented with
charcoal-stripped FCS (Hyclone) and steroid hormones were
added in phenol red-free DMEM. In reporter assays, 0.5 g of firefly
luciferase reporter, 1 ng CMV-renilla luciferase as an internal con-
trol, and 3 g of the indicated DNA were transfected. Hormones
and TSA were added 24 hr after transfection and assays were per-
formed 48 hr after transfection. In RNAi experiments, RA was
added 72 hr after transfection and assays were performed 96 hr
after transfection. Luciferase activities shown represent ratios of
firefly luciferase to renilla luciferase internal control values, and
normalized luciferase activities are the average ± SD from three
independent transfections. F9 cells were stained by incubation with
SSEA-1 antibody (dilution 1:40) and with goat-anti-mouse-FITC
conjugated antibody (Zymed, dilution 1:400). For detection of apo-
ptosis, F9 cells were stained with Annexin V-biotin antibody (Boeh-
ringer Mannheim, dilution 1:50) and with streptavidin-PE-Cy5 (BD
Pharmingen, dilution 1:500) and subjected to flow cytometry
analysis.
GST Pull-Down Assays
GST fusion proteins were expressed and purified from the E. coli
BL21 (DE3) strain. Total bacterial extracts were prepared in NETNlysis buffer (20 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5%
NP40) supplemented with protease inhibitors (Complete; Roche),
and GST fusion proteins were purified on glutathione-Sepharose
4B beads (Amersham Pharmacia Biotech). 35S-methionine-labeled
proteins were prepared by in vitro transcription/translation using
the TNT coupled reticulocyte lysate system (Promega) and equal
amounts of GST fusion proteins on glutathione beads were incu-
bated with in vitro translation products in NETN buffer for 2 hr,
washed, and fractionated by SDS-PAGE.
Western Blotting and Coimmunoprecipitation
Cells were lysed in RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl,
1% NP-40, 0.5% deoxycholic acid, and 0.1% SDS) supplemented
with protease inhibitors (Complete; Roche), and 0.2 nM PMSF and
proteins were separated on 8%–14% SDS-PAGE gels. Cell lysates
and conditioned media (20 l) from F9 cells were subjected to SDS-
PAGE gels under reducing and nonreducing conditions, respec-
tively. Proteins were transferred to polyvinylidine difluoride mem-
branes (Immobilon-P, Millipore) and Western blots were probed
with the indicated antibodies. For coimmunoprecipitations, cells
were lysed in ELB buffer (0.25 M NaCl, 0.1% NP-40, 50 mM HEPES,
pH 7.3) supplemented with protease inhibitors and PMSF. Lysates
were incubated with IgG-coated sepharose beads (Amersham
Pharmacia Biotech) to immunoprecipitate TAP-tagged proteins19,
indicated as anti-TAP, or with protein A beads coated with the indi-
cated antibodies, and the precipitates were separated on SDS-
PAGE gels. For ChIP analysis, PRAME polyclonal rabbit antisera
440 and 442 were used.
Mouse Tumor Xenografts
Female 5- to 6-week-old athymic BALB-C nude mice (nu/nu) were
s.c. implanted with 1 × 106 cells bilaterally into the axial regions.
Each mouse received A375-PRAMEKD cells in its right flank and
control A375 cells in its left flank. Mice were randomized into treat-
ment groups and treated with 5 mg/kg RA or vehicle (ethanol in
sunflower oil) orally with a 20-gauge intragastric feeding tube daily.
The pRS vector which was used to generate A375-PRAMEKD cells
is a self-inactivating retroviral vector, to prevent re-activation and
spreading of virus (Brummelkamp et al., 2002a; Brummelkamp et
al., 2002b). The experiment was performed twice, with n = 20 and
n = 10 mice, and results were similar in both experiments.
Supplemental Data
Supplemental Data include three figures and Supplemental Experi-
mental Procedures and can be found with this article online at
http://www.cell.com/cgi/content/full/122/6/835/DC1/.
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